Resveratrol suppresses human colon cancer cell proliferation and induces apoptosis via targeting the pentose phosphate and the talin-FAK signaling pathways-A proteomic approach

Proteome Science

Volumn 9, Issue , 2011, Pages

  Vanamala, Jairam ^a,b   Radhakrishnan, Sridhar ^a   Reddivari, Lavanya ^a   Bhat, Vadiraja B ^c,d   Ptitsyn, Andrey ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^c SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^d AGILENT TECHNOLOGIES   (United States)

Author keywords

Insulin like Growth Factor 1 (IGF 1); ResveratrolProteomicsTalinFocal Adhesion Kinase (FAK)Pentose Phosphate Pathway

Indexed keywords

PENTOSE PHOSPHATE; RESVERATROL; SOMATOMEDIN C; TALIN; TRANSKETOLASE;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE PROGRESSION; CELL PROLIFERATION; COLON CANCER; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HUMAN CELL; PROTEIN ANALYSIS; PROTEOMICS; SIGNAL TRANSDUCTION;

RICE STRIPE VIRUS;

EID: 80051634012     PISSN: None     EISSN: 14775956     Source Type: Journal    
DOI: 10.1186/1477-5956-9-49     Document Type: Article

References (63)

1. Ptitsyn AA, Weil MM, Thamm DH. Systems biology approach to identification of biomarkers for metastatic progression in cancer. BMC Bioinformatics 2008, 9(Suppl 9):S8. 10.1186/1471-2105-9-S9-S8, 2638148, 19091031.
2. Joo JI, Kim DH, Choi JW, Yun JW. Proteomic analysis for antiobesity potential of capsaicin on white adipose tissue in rats fed with a high fat diet. J Proteome Res 2010, 9(6):2977-2987. 10.1021/pr901175w, 20359164.
3. Sundsten T, Ortsater H. Proteomics in diabetes research. Mol Cell Endocrinol 2009, 297(1-2):93-103. 10.1016/j.mce.2008.06.018, 18657591.
4. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997, 275(5297):218-220. 10.1126/science.275.5297.218, 8985016.
5. Stewart JR, Artime MC, O'Brian CA. Resveratrol: a candidate nutritional substance for prostate cancer prevention. J Nutr 2003, 133(7 Suppl):2440S-2443S.
6. Vanamala J, Reddivari L, Radhakrishnan S, Tarver C. Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways. BMC Cancer 2010, 10:238. 10.1186/1471-2407-10-238, 2891636, 20504360.
7. Hart LS, Dolloff NG, Dicker DT, Koumenis C, Christensen JG, Grimberg A, El-Deiry WS. Human colon cancer stem cells are enriched by insulin-like growth factor-1 and are sensitive to figitumumab. Cell Cycle 2011, 10(14).
8. Kim AL, Zhu Y, Zhu H, Han L, Kopelovich L, Bickers DR, Athar M. Resveratrol inhibits proliferation of human epidermoid carcinoma A431 cells by modulating MEK1 and AP-1 signalling pathways. Exp Dermatol 2006, 15(7):538-546. 10.1111/j.1600-0625.2006.00445.x, 16761963.
9. Kuo PL, Chiang LC, Lin CC. Resveratrol- induced apoptosis is mediated by p53-dependent pathway in Hep G2 cells. Life Sci 2002, 72(1):23-34. 10.1016/S0024-3205(02)02177-X, 12409142.
10. Kuwajerwala N, Cifuentes E, Gautam S, Menon M, Barrack ER, Reddy GP. Resveratrol induces prostate cancer cell entry into s phase and inhibits DNA synthesis. Cancer Res 2002, 62(9):2488-2492.
11. Lin HY, Sun M, Tang HY, Simone TM, Wu YH, Grandis JR, Cao HJ, Davis PJ, Davis FB. Resveratrol causes COX-2- and p53-dependent apoptosis in head and neck squamous cell cancer cells. J Cell Biochem 2008, 104(6):2131-2142. 10.1002/jcb.21772, 18446786.
12. Manna SK, Mukhopadhyay A, Aggarwal BB. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol 2000, 164(12):6509-6519.
13. Park JW, Choi YJ, Suh SI, Baek WK, Suh MH, Jin IN, Min DS, Woo JH, Chang JS, Passaniti A, et al. Bcl-2 overexpression attenuates resveratrol-induced apoptosis in U937 cells by inhibition of caspase-3 activity. Carcinogenesis 2001, 22(10):1633-1639. 10.1093/carcin/22.10.1633, 11577002.
14. Das S, Chaudhury A, Ng KY. Preparation and evaluation of zinc-pectin-chitosan composite particles for drug delivery to the colon: role of chitosan in modifying in vitro and in vivo drug release. Int J Pharm 2011, 406(1-2):11-20. 10.1016/j.ijpharm.2010.12.015, 21168477.
15. Das S, Ng KY. Impact of glutaraldehyde on in vivo colon-specific release of resveratrol from biodegradable pectin-based formulation. J Pharm Sci 2010, 99(12):4903-4916. 10.1002/jps.22212, 20572052.
16. Das S, Ng KY. Colon-specific delivery of resveratrol: optimization of multi-particulate calcium-pectinate carrier. Int J Pharm 2010, 385(1-2):20-28. 10.1016/j.ijpharm.2009.10.016, 19833179.
17. Patel KR, Brown VA, Jones DJ, Britton RG, Hemingway D, Miller AS, West KP, Booth TD, Perloff M, Crowell JA, et al. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res 2010, 70(19):7392-7399. 10.1158/0008-5472.CAN-10-2027, 2948608, 20841478.
18. Boocock DJ, Faust GE, Patel KR, Schinas AM, Brown VA, Ducharme MP, Booth TD, Crowell JA, Perloff M, Gescher AJ, et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 2007, 16(6):1246-1252. 10.1158/1055-9965.EPI-07-0022, 17548692.
19. Juan ME, Vinardell MP, Planas JM. The daily oral administration of high doses of trans-resveratrol to rats for 28 days is not harmful. J Nutr 2002, 132(2):257-260.
20. Juan ME, Wenzel U, Daniel H, Planas JM. Resveratrol induces apoptosis through ROS-dependent mitochondria pathway in HT-29 human colorectal carcinoma cells. J Agric Food Chem 2008, 56(12):4813-4818. 10.1021/jf800175a, 18522405.
21. LeRoith D, Roberts CT. The insulin-like growth factor system and cancer. Cancer Lett 2003, 195(2):127-137. 10.1016/S0304-3835(03)00159-9, 12767520.
22. Vanamala J, Tarver CC, Murano PS. Obesity-enhanced colon cancer: functional food compounds and their mechanisms of action. Curr Cancer Drug Targets 2008, 8(7):611-633. 10.2174/156800908786241087, 18991570.
23. Ahmed RL, Thomas W, Schmitz KH. Interactions between insulin, body fat, and insulin-like growth factor axis proteins. Cancer Epidemiol Biomarkers Prev 2007, 16(3):593-597. 10.1158/1055-9965.EPI-06-0775, 17372257.
24. Frystyk J. Free insulin-like growth factors -- measurements and relationships to growth hormone secretion and glucose homeostasis. Growth Horm IGF Res 2004, 14(5):337-375. 10.1016/j.ghir.2004.06.001, 15336229.
25. Liang J, Slingerland JM. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2003, 2(4):339-345.
26. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nature Rev 2005, 4(12):988-1004.
27. Boros LG, Lee PW, Brandes JL, Cascante M, Muscarella P, Schirmer WJ, Melvin WS, Ellison EC. Nonoxidative pentose phosphate pathways and their direct role in ribose synthesis in tumors: is cancer a disease of cellular glucose metabolism?. Med Hypotheses 1998, 50(1):55-59. 10.1016/S0306-9877(98)90178-5, 9488183.
28. Vizan P, Alcarraz-Vizan G, Diaz-Moralli S, Solovjeva ON, Frederiks WM, Cascante M. Modulation of pentose phosphate pathway during cell cycle progression in human colon adenocarcinoma cell line HT29. Int J Cancer 2009, 124(12):2789-2796. 10.1002/ijc.24262, 19253370.
29. Ramos-Montoya A, Lee WN, Bassilian S, Lim S, Trebukhina RV, Kazhyna MV, Ciudad CJ, Noe V, Centelles JJ, Cascante M. Pentose phosphate cycle oxidative and nonoxidative balance: A new vulnerable target for overcoming drug resistance in cancer. Int J Cancer 2006, 119(12):2733-2741. 10.1002/ijc.22227, 17019714.
30. Albelda SM. Role of integrins and other cell adhesion molecules in tumor progression and metastasis. Lab Invest 1993, 68(1):4-17.
31. Stupack DG, Cheresh DA. Get a ligand, get a life: integrins, signaling and cell survival. J Cell Sci 2002, 115(Pt 19):3729-3738.
32. Mizejewski GJ. Role of integrins in cancer: survey of expression patterns. Proc Soc Exp Biol Med 1999, 222(2):124-138. 10.1046/j.1525-1373.1999.d01-122.x, 10564536.
33. Zhu H, Liu XW, Cai TY, Cao J, Tu CX, Lu W, He QJ, Yang B. Celastrol acts as a potent antimetastatic agent targeting beta1 integrin and inhibiting cell-extracellular matrix adhesion, in part via the p38 mitogen-activated protein kinase pathway. J Pharmacol Exp Ther 2010, 334(2):489-499. 10.1124/jpet.110.165654, 20472666.
34. Chen HC, Appeddu PA, Parsons JT, Hildebrand JD, Schaller MD, Guan JL. Interaction of focal adhesion kinase with cytoskeletal protein talin. J Biol Chem 1995, 270(28):16995-16999. 10.1074/jbc.270.28.16995, 7622520.
35. Parsons JT, Martin KH, Slack JK, Taylor JM, Weed SA. Focal adhesion kinase: a regulator of focal adhesion dynamics and cell movement. Oncogene 2000, 19(49):5606-5613. 10.1038/sj.onc.1203877, 11114741.
36. Yamamoto D, Sonoda Y, Hasegawa M, Funakoshi-Tago M, Aizu-Yokota E, Kasahara T. FAK overexpression upregulates cyclin D3 and enhances cell proliferation via the PKC and PI3-kinase-Akt pathways. Cell Signal 2003, 15(6):575-583. 10.1016/S0898-6568(02)00142-0, 12681445.
37. Radhakrishnan S, Reddivari L, Das U, Scalafani R, Vanamala J. Resveratrol potentiates grape seed extract induced human cancer cell apoptosis via activation of p53-dependent signaling pathways. Front Biosci (Elite Ed) 2011, 3:1509-1523.
38. Mukherjee S, Dudley JI, Das DK. Dose-dependency of resveratrol in providing health benefits. Dose Response 2010, 8(4):478-500. 10.2203/dose-response.09-015.Mukherjee, 2990065, 21191486.
39. Choi JS, Paek AR, Kim SY, You HJ. GIPC mediates the generation of reactive oxygen species and the regulation of cancer cell proliferation by insulin-like growth factor-1/IGF-1R signaling. Cancer Lett 2010, 294(2):254-263. 10.1016/j.canlet.2010.02.007, 20206441.
40. Schlaepfer DD, Mitra SK. Multiple connections link FAK to cell motility and invasion. Curr Opin Genet Dev 2004, 14(1):92-101. 10.1016/j.gde.2003.12.002, 15108811.
41. Mitra SK, Mikolon D, Molina JE, Hsia DA, Hanson DA, Chi A, Lim ST, Bernard-Trifilo JA, Ilic D, Stupack DG, et al. Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumors. Oncogene 2006, 25(44):5969-5984. 10.1038/sj.onc.1209588, 16682956.
42. Mitra SK, Schlaepfer DD. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol 2006, 18(5):516-523. 10.1016/j.ceb.2006.08.011, 16919435.
43. Gabarra-Niecko V, Schaller MD, Dunty JM. FAK regulates biological processes important for the pathogenesis of cancer. Cancer Metastasis Rev 2003, 22(4):359-374. 10.1023/A:1023725029589, 12884911.
44. de la Lastra CA, Villegas I. Resveratrol as an antioxidant and pro-oxidant agent: mechanisms and clinical implications. Biochem Soc Trans 2007, 35(Pt 5):1156-1160.
45. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324(5930):1029-1033. 10.1126/science.1160809, 2849637, 19460998.
46. Warburg O. On respiratory impairment in cancer cells. Science 1956, 124(3215):269-270.
47. Duvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL, Triantafellow E, Ma Q, Gorski R, Cleaver S, et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell 2010, 39(2):171-183. 10.1016/j.molcel.2010.06.022, 2946786, 20670887.
48. Vanamala J, Reddivari L. Resveratrol suppresses insulin-like growth factor-1 promoted colon cancer cell growth via activation of p53/AMPK/TSC-2 and suppression of IGF-1R/Akt/mTOR signaling pathways. AACR Meeting Abstracts: April 13 2009; Denver 2009,
49. Sakamoto S, McCann RO, Dhir R, Kyprianou N. Talin1 promotes tumor invasion and metastasis via focal adhesion signaling and anoikis resistance. Cancer Res 2010, 70(5):1885-1895. 10.1158/0008-5472.CAN-09-2833, 2836205, 20160039.
50. McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG, Frame MC. The role of focal-adhesion kinase in cancer-a new therapeutic opportunity. Nat Rev Cancer 2005, 5(7):505-515. 10.1038/nrc1647, 16069815.
51. Valentijn AJ, Zouq N, Gilmore AP. Anoikis. Biochem Soc Trans 2004, 32(Pt3):421-425.
52. Frisch SM, Screaton RA. Anoikis mechanisms. Curr Opin Cell Biol 2001, 13(5):555-562. 10.1016/S0955-0674(00)00251-9, 11544023.
53. Bahr C, Groner B. The IGF-1 receptor and its contributions to metastatic tumor growth-novel approaches to the inhibition of IGF-1R function. Growth Factors 2005, 23(1):1-14. 10.1080/08977190400020229, 16019422.
54. Dudley J, Das S, Mukherjee S, Das DK. Resveratrol, a unique phytoalexin present in red wine, delivers either survival signal or death signal to the ischemic myocardium depending on dose. J Nutr Biochem 2009, 20(6):443-452. 10.1016/j.jnutbio.2008.05.003, 18789672.
55. Sieg DJ, Hauck CR, Ilic D, Klingbeil CK, Schaefer E, Damsky CH, Schlaepfer DD. FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol 2000, 2(5):249-256. 10.1038/35010517, 10806474.
56. Liu W, Bloom DA, Cance WG, Kurenova EV, Golubovskaya VM, Hochwald SN. FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells. Carcinogenesis 2008, 29(6):1096-1107. 10.1093/carcin/bgn026, 2902396, 18263593.
57. Zheng D, Golubovskaya V, Kurenova E, Wood C, Massoll NA, Ostrov D, Cance WG, Hochwald SN. A novel strategy to inhibit FAK and IGF-1R decreases growth of pancreatic cancer xenografts. Mol Carcinog 2010, 49(2):200-209. 3136037, 19885860.
58. Sonoda Y, Matsumoto Y, Funakoshi M, Yamamoto D, Hanks SK, Kasahara T. Anti-apoptotic role of focal adhesion kinase (FAK). Induction of inhibitor-of-apoptosis proteins and apoptosis suppression by the overexpression of FAK in a human leukemic cell line, HL-60. J Biol Chem 2000, 275(21):16309-16315. 10.1074/jbc.275.21.16309, 10821872.
59. Shibue T, Weinberg RA. Integrin beta1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs. Proc Natl Acad Sci USA 2009, 106(25):10290-10295. 10.1073/pnas.0904227106, 2700942, 19502425.
60. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003, 19(2):185-193. 10.1093/bioinformatics/19.2.185, 12538238.
61. Smirnova NP, Ptitsyn AA, Austin KJ, Bielefeldt-Ohmann H, Van Campen H, Han H, van Olphen AL, Hansen TR. Persistent fetal infection with bovine viral diarrhea virus differentially affects maternal blood cell signal transduction pathways. Physiol Genomics 2009, 36(3):129-139. 2646461, 19018046.
62. Savitzky A, Golay M. Smoothing and differentiation of data by simplified least squares procedures. Anal Chem 1964, 36:1627-1639.
63. De La Haba G, Leder IG, Racker E. Crystalline transketolase from bakers' yeast: isolation and properties. J Biol Chem 1955, 214(1):409-426.